You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
港股異動丨生物科技股集體走強,康諾亞升超11%創逾1個月新高
格隆匯 07-13 10:59
格隆匯7月13日丨港股市場整體活躍之際,生物科技股集體走強,其中,康諾亞-B(2162.HK)拉昇升超11%至51.4港元,股價創5月底以來新高。行業消息面上,7月4日醫保局發佈《談判藥品續約規則》及《非獨家藥品競價規則》公開徵求意見。機構普遍認為新續約規則有利於引導對創新藥長期定價機制的形成並給予行業更明確的長期預期,體現醫保對創新的支持。另外個股消息面上,7月3日,康諾亞、諾誠健華聯合宣佈,雙方合資公司天諾健成研發的CD20xCD3雙特異性抗體ICP-B02在中國完成首例患者皮下注射給藥。皮下注射也是該臨牀試驗在靜脈輸注給藥方式新增的給藥途徑。目前,ICP-B02正在中國開展治療CD20 B細胞血液瘤的臨牀研究。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account